Brochure
3 Nov 2021

Presentation: Achieving Bioavailability Enhancement for Poorly Soluble Compounds

PDF 2.6 MB

A large and increasing fraction of orally administered small molecules in pharma company pipelines have poor oral absorption due to low aqueous solubility or dissolution rate. To address this trend, evaluating formulation approaches for increasing oral bioavailability are becoming routine early on in formulation development programs. Selecting the appropriate technology for your compound requires careful consideration of the compound physicochemical properties, target dose and pharmacokinetic profile, as well as overall market image. In this on-demand webinar, hear about some of the most common bioavailability-enhancing technologies for poorly soluble compounds and a strategic framework for identifying and selecting the appropriate technology. A case study is presented.

Content provided by our supplier

Lonza

  • CH
  • 2015
    On CPHI since
  • 5000+
    Employees
Company types
Contract Service
Manufacturer/Innovator

Other Content from Lonza (35)